@article{barata_evolving_2017,
	title = {The {Evolving} {Treatment} {Landscape} of {Advanced} {Renal} {Cell} {Carcinoma} in {Patients} {Progressing} after {VEGF} {Inhibition}},
	volume = {4},
	issn = {2203-5826},
	doi = {10.15586/jkcvhl.2017.69},
	abstract = {Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing data on subsequent therapies is crucial to define an optimal treatment sequence following first-line failure. This review examines the data supporting currently approved agents in this setting and provides a framework for decision-making regarding treatment sequencing beyond first-line therapy with VEGFR TKIs.},
	language = {eng},
	number = {2},
	journal = {Journal of kidney cancer and VHL},
	author = {Barata, Pedro C. and Ornstein, Moshe C. and Garcia, Jorge A.},
	year = {2017},
	pmid = {28725539},
	pmcid = {PMC5515898},
	keywords = {Clear Cell Renal Cell Carcinoma, Kidney, ccRCC},
	pages = {10--18},
}

{"_id":"rfY83tdFeP7cNA5yJ","bibbaseid":"barata-ornstein-garcia-theevolvingtreatmentlandscapeofadvancedrenalcellcarcinomainpatientsprogressingaftervegfinhibition-2017","author_short":["Barata, P. C.","Ornstein, M. C.","Garcia, J. A."],"bibdata":{"bibtype":"article","type":"article","title":"The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition","volume":"4","issn":"2203-5826","doi":"10.15586/jkcvhl.2017.69","abstract":"Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing data on subsequent therapies is crucial to define an optimal treatment sequence following first-line failure. This review examines the data supporting currently approved agents in this setting and provides a framework for decision-making regarding treatment sequencing beyond first-line therapy with VEGFR TKIs.","language":"eng","number":"2","journal":"Journal of kidney cancer and VHL","author":[{"propositions":[],"lastnames":["Barata"],"firstnames":["Pedro","C."],"suffixes":[]},{"propositions":[],"lastnames":["Ornstein"],"firstnames":["Moshe","C."],"suffixes":[]},{"propositions":[],"lastnames":["Garcia"],"firstnames":["Jorge","A."],"suffixes":[]}],"year":"2017","pmid":"28725539","pmcid":"PMC5515898","keywords":"Clear Cell Renal Cell Carcinoma, Kidney, ccRCC","pages":"10–18","bibtex":"@article{barata_evolving_2017,\n\ttitle = {The {Evolving} {Treatment} {Landscape} of {Advanced} {Renal} {Cell} {Carcinoma} in {Patients} {Progressing} after {VEGF} {Inhibition}},\n\tvolume = {4},\n\tissn = {2203-5826},\n\tdoi = {10.15586/jkcvhl.2017.69},\n\tabstract = {Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing data on subsequent therapies is crucial to define an optimal treatment sequence following first-line failure. This review examines the data supporting currently approved agents in this setting and provides a framework for decision-making regarding treatment sequencing beyond first-line therapy with VEGFR TKIs.},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {Journal of kidney cancer and VHL},\n\tauthor = {Barata, Pedro C. and Ornstein, Moshe C. and Garcia, Jorge A.},\n\tyear = {2017},\n\tpmid = {28725539},\n\tpmcid = {PMC5515898},\n\tkeywords = {Clear Cell Renal Cell Carcinoma, Kidney, ccRCC},\n\tpages = {10--18},\n}\n\n\n\n","author_short":["Barata, P. C.","Ornstein, M. C.","Garcia, J. A."],"key":"barata_evolving_2017","id":"barata_evolving_2017","bibbaseid":"barata-ornstein-garcia-theevolvingtreatmentlandscapeofadvancedrenalcellcarcinomainpatientsprogressingaftervegfinhibition-2017","role":"author","urls":{},"keyword":["Clear Cell Renal Cell Carcinoma","Kidney","ccRCC"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero-group/VHLA/5946245","dataSources":["ePsAR3pjtvuSxA4wN"],"keywords":["clear cell renal cell carcinoma","kidney","ccrcc"],"search_terms":["evolving","treatment","landscape","advanced","renal","cell","carcinoma","patients","progressing","vegf","inhibition","barata","ornstein","garcia"],"title":"The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition","year":2017}